Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% (USRLD: Epiduo Forte). A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples. Adapalene works by affecting the growth of cells and decreasing swelling and inflammation and Benzoyl Peroxide works by reducing the amount of acne-causing bacteria and by causing the skin to dry and peel off. The drug will be manufactured at group's topical facility at Ahmedabad. Adapalene and Benzoyl Peroxide Topical Gel had a market size of USD 195 mn (as per IQVIA MAT April 22).

The group now has 315 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 364.65 as compared to the previous close of Rs. 362.95. The total number of shares traded during the day was 32329 in over 823 trades.

The stock hit an intraday high of Rs. 366.00 and intraday low of 358.00. The net turnover during the day was Rs. 11744012.00.

Source : Equity Bulls

Keywords

ZydusLifesciences CadilaHealthcare INE010B01027 FinalApproval USFDA AdapaleneandBenzoylPeroxide TopicalGel